PDCD1 and colorectal adenocarcinoma: Furthermore, our preclinical studies showed that penpulimab (8 mg/kg and 10 mg/kg body weight) had potent antitumor activities in human PD-1 knock-in tumor model bearing colorectal adenocarcinoma xenografts and SCID/beige mice model subcutaneously inoculated with Raji-PD-L1 cells plus freshly isolated human peripheral blood mononuclear cells (data not shown).